Connect with us

featured

DEA Judge Sides With Agency On Proposal To Ban Two Psychedelics Despite Challenge From Scientific Researchers

Published

on


A Drug Enforcement Administration judge has formally sided with the agency in its attempt to ban two psychedelic compounds that researchers say hold significant therapeutic potential, recommending that they be placed in Schedule I of the Controlled Substances Act (CSA).

In a ruling on Friday, DEA Administrative Law Judge (ALJ) Paul Soeffing said he advised the agency to move forward with its plan to place the psychedelics—2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC)—in Schedule I.

This follows administrative hearings where researchers and advocates, including Panacea Plant Sciences (PPS) and Students for Sensible Drug Policy (SSDP), have fought against DEA to ensure that the psychedelics can continue to be utilized in research.

But in the 118-page ruling, Soeffing ultimately said that “the record contains substantial evidence regarding the eight factors required for consideration under 21 U.S.C. § 811(c) to support recommending the scheduling of DOI and DOC,” referring to an administrative standard for determining the health risks and benefits of substances before when placing them in the CSA.

“Furthermore, I find that the record contains substantial evidence regarding the three factors required for consideration under 21 U.S.C. § 812(b)(1) to support recommending the placement of DOI and DOC in Schedule I,” he said, adding that the fact that the United Nations put DOC specifically on its own controlled substances list justifies its prohibition.

The bulk of the recommendation, which must be approved by the DEA administrator before potentially being codified, recounts the competing arguments between DEA and organizations opposing the scheduling action. But this ruling could reignite an ongoing legal challenge that PPS levied against the agency, challenging the fundamental constitutionality of the ALJ proceedings in drug scheduling rulemaking.

“It’s not a surprise that a DEA employee would side with the DEA,” PPS CEO David Heldreth told Marijuana Moment on Friday. “We find that the supposed impartiality of the judge is highly questionable due to that, and we plan to appeal this ruling and continue our lawsuit against the DEA.”

SSDP was among stakeholders who requested the psychedelics hearing in the first place, in hopes of challenging what they view as a lack of evidence justifying DEA’s proposed ban. Researchers have pointed out that DOI and DOC, as currently unscheduled substances, have been key components in psychedelics research that show potential in the treatment of anxiety and depression, for example.

Researchers have also argued that DEA has failed to meet the statutory burden of demonstrating that either psychedelic compound has high abuse potential. There are no documented cases in medical literature of “distressing responses or death” related to human consumption of DOI, nor has there been any established evidence of a high risk of dependence, SSDP said in a pre-hearing filing in July.

The initial scheduling of the administrative hearing on DOI and DOC came about two months after a federal court dismissed the case challenging the constitutionality of DEA’s process for adjudicating scheduling actions as the agency has pursued the  ban the two psychedelic compounds.

DEA first attempted to ban DOI and DOC in 2022, only to withdraw the proposal amid pushback from the scientific community. The agency separately withdrew from a proposal to ban five different tryptamine psychedelics in 2022.

In 2023, DEA announced that it would be trying to enact the DOC and DOI ban again. The agency’s notice about the scheduling proposal still lacks evidence that directly connects the compounds to serious adverse health events or demonstrated a high abuse potential.

“To date, there are no reports of distressing responses or death associated with DOI in medical literature,” it said. “The physiological dependence liability of DOI and DOC in animals and humans is not reported in scientific and medical literature.”

DEA said that anecdotal reports posted by people online signaled that the substances have hallucinogenic effects, making it “reasonable to assume that DOI and DOC have substantial capability to be a hazard to the health of the user and to the safety of the community.”

It did point to one report of a death of a person who had used DOC in combination with two other unspecified drugs—as well as two reports of hospitalizations that it said were attributable to the use of DOC with other drugs—but scientists say that hardly constitutes reason enough to place them in the most strictly controlled schedule.

Kat Murti, executive director of SSDP, said in a press release on Monday that the timing of the DEA ALJ’s new recommendations, which coincided with World Psychedelics Day, is “no coincidence.”

“The DEA has relied on similar shady tricks throughout this process—such as announcing their intent to schedule these substances during the winter holidays in 2023 after withdrawing their 2022 attempt, which SSDP also opposed,” she said. “Their strategy throughout has been to try to sneak this ruling by unnoticed because they know the American public and anyone who cares about public health is on our side.”

“DOI and DOC are crucial tools for understanding how serotonin works in the body,” Murti said. “By adding them to Schedule I, the DEA is forcing medical science into the dark ages.”

Alaina Jaster, who has a PhD in pharmacology and Toxicology and serves as co-chair of SSDP’s Science Policy Committee, said the DEA judge’s decision is “disappointing and the almost 120-page record seems to reflect a very different reality than the one I experienced on the stand” when testifying in the case.

“Despite the stipulations of fact that themselves state there is no documented use of DOI, no deaths or overdose, no diversion, and it’s impossible to know whether anecdotal reports which the DEA rely upon actually contain DOI, the administrative judge has recommended placing DOI/DOC in schedule I,” she said. “As someone who has extensively studied the pharmacodynamics and pharmacokinetics of DOI and related psychedelics, it’s baffling to me that the government is going after DOI/DOC.”

In the background of this latest development, proceedings on a proposed rule to move marijuana from Schedule I to Schedule III have stalled amid challenges from witnesses in the administrative hearings. Those hearings are being overseen by a different DEA ALJ, John Mulrooney.

Amid the stalled marijuana rescheduling process that’s carried over from the last presidential administration, congressional researchers are reiterating that lawmakers could enact the reform themselves with “greater speed and flexibility” if they so choose, while potentially avoiding judicial challenges.

Meanwhile, last month a Senate committee advanced the confirmation of Terrance Cole to become the administrator of DEA amid the ongoing review of a marijuana rescheduling proposal that he’s refused to commit to enacting.

Cole—who has previously voiced concerns about the dangers of marijuana and linked its use to higher suicide risk among youth—said he would “give the matter careful consideration after consulting with appropriate personnel within the Drug Enforcement Administration, familiarizing myself with the current status of the regulatory process, and reviewing all relevant information.”

However, during an in-person hearing before the Judiciary Committee in April, he said examining the rescheduling proposal will be “one of my first priorities” if he was confirmed for the role, saying it’s “time to move forward” on the stalled process—but again without clarifying what end result he would like to see.

“I’m not familiar exactly where we are, but I know the process has been delayed numerous times—and it’s time to move forward,” he said at the time. “I need to understand more where [agencies] are and look at the science behind it and listen to the experts and really understand where they are in the process.”

Cole also said he feels it’s appropriate to form a “working group” to look at the federal-state marijuana law disconnect in order to “stay ahead of it.”

Read the DEA ALJ’s ruling and recommendation on the psychedelics ban below: 

‘Justice Is Still Being Denied’ To People With Past Marijuana Convictions As Legalization Spreads, Review By Advocacy Group Says

Image courtesy of Students for Sensible Drug Policy.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Become a patron at Patreon!





Source link

mscannabiz.com
Author: mscannabiz.com

MScannaBIZ for all you Mississippi Cannabis News and Information.

featured

Federal Judge Rejects Pennsylvania Prosecutor’s Lawsuit Challenging Ban On Marijuana Consumer Gun Ownership

Published

on


A district judge in Pennsylvania has dismissed a lawsuit challenging the federal government’s ban on gun ownership by state-legal medical marijuana patients, ruling that the prohibition is constitutional and that patients can avoid legal jeopardy “by simply choosing an alternative treatment.”

“Plaintiffs have no constitutional right to use marijuana—medical or otherwise, and there are no allegations that medical marijuana is the only available treatment for their medical conditions,” U.S. District Judge Cathy Bissoon, an Obama appointee, wrote in a decision this week.

The suit was filed in January of last year by Warren County District Attorney Robert Greene, who is a registered medical cannabis patient in the state, and with the Second Amendment Foundation (SAF), which advocates for gun rights.

At the heart of the case is the federal statute known as Section 922(g)(3), which prevents someone who is an “unlawful user” of an illegal drug from buying or possessing firearms.

The Department of Justice filed a motion to dismiss last November, arguing that the suit “fails as a matter of law by challenging a constitutional statute.”

Greene’s participation was especially notable. The complaint said the county prosecutor had intended to “lawfully purchase, possess, and utilize firearms and ammunition so that he may exercise his constitutional right to keep and bear arms for self-defense and all other lawful purposes” but was barred from doing because of his status as a medical marijuana patient.

Another plaintiff, Bloomberg resident and Second Amendment Foundation member James Irey already owns firearms, the suit said, but wanted to obtain a medical marijuana registration at the recommendation of his doctor.

Plaintiffs alleged the prohibition on gun ownership by cannabis users was unconstitutional, both on its face and applied to Greene and Irey. Attorneys argued that the federal law is distinct from other statutes that limit gun ownership by potentially dangerous individuals, pointing out that other restrictions are “only permitted the deprivation of one’s Second Amendment rights after a hearing, providing for due process, and then, only temporarily.”

“To say that an individual loses their right to keep and bear arms for self-defense and other lawful purposes merely because they may be ‘intoxicated’ at some point in time, by virtue of using a lawful medicine pursuant to state law, eludes logic,” the lawsuit said.

Bissoon disagreed, dismissing the challenge for failure to state a claim.

“Plaintiff Irey already possesses numerous firearms and can retain them by simply choosing an alternative treatment,” she wrote. “Plaintiff Green can purchase and possess firearms if he stops participating in the medical marijuana program.”

“Choosing to refrain from engaging in federally unlawful behavior,” the judge added, referring to cannabis use, “is not a burdensome ask.”

The case, filed in U.S. District Court for the Western District of Pennsylvania, is Greene v. Bondi (24-00021).

Bissoon’s ruling acknowledges that “modern Second Amendment jurisprudence is rapidly evolving,” but she said the decision’s reasoning “reflects the current legal landscape in the Third Circuit,” which includes Pennsylvania.

Unlike some other recent federal court rulings around the constitutionality of the restriction—such as in the U.S. Court of Appeals for the Eighth and Fifth Circuits—the district court dismissal maintains that the law is sufficiently similar to other historical government limits on the Second Amendment, such as preventing firearm possession by intoxicated people and individuals with mental illness.

“After careful consideration, the Court agrees that the Government has shown that Sections 922(g)(3) and (d)(3) are ‘relevantly similar’ to historical regulations aimed at preventing potentially dangerous persons from possessing and using firearms, including the mentally ill and the intoxicated,” the June 30 ruling says. “Although the Court of Appeals for the Third Circuit has not yet addressed directly the provisions challenged here, this finding is consistent with the overwhelming weight of authority upholding the facial constitutionality of Sections 922(g)(3) and/or (d)(3) and related regulations.”

Bissoon’s ruling dismisses the suit with prejudice, meaning the case is now closed and cannot be amended and refiled. “Because the Court’s decision rests primarily on legal conclusions and not on insufficient factual allegations,” it says, “it finds that further amendment would be futile.”

Courts in recent years have been divided on whether the federal government’s ban on gun ownership by cannabis users is lawful, especially when broadly applied.

Some have said the blanket ban on gun and ammunition possession infringes on the Second Amendment—at least as applied to certain individual cases—because there’s no historical justification for such a broad restriction on an entire category of people.

The matter could soon be taken up by the U.S. Supreme Court. In a recent petition for review by justices, U.S. Solicitor General D. John Sauer argued that despite recent appeals court decisions calling the constitutionality of the firearms ban into question, the restriction is nevertheless lawful.

“Section 922(g)(3) complies with the Second Amendment,” the government’s filing in that case, U.S. v. Hemani, says. “That provision targets a category of persons who pose a clear danger of misusing firearms: habitual users of unlawful drugs.”

The federal statute “bars their possession of firearms only temporarily,” the government petition says, “and leaves it within their power to lift the restriction at any time; anyone who stops habitually using illegal drugs can resume possessing firearms.”

Notably, while the government mentioned “habitual” users of illegal drugs 40 times in its filing, that word does not itself appear in 922(g)(3). The language of the statute prohibits anyone “who is an unlawful user of or addicted to any controlled substance” from purchasing or possessing firearms or ammunition.

A reply brief from the plaintiff in the case is due to the Supreme Court by July 21.

While DOJ is asking the high court to take up the Hemani case, at least two other, similar cases are waiting in the wings: U.S. v. Cooper and U.S. v. Baxter both of which also hinge on the constitutionality of 922(g)(3).

In Cooper, an Eighth Circuit U.S. Court of Appeals panel dismissed a three-year prison sentence against a person convicted for possession of a firearm while being an active user of marijuana. Judges in that case ruled that government’s prohibition on gun ownership by drug users is justified only in certain circumstances—not always.

“Nothing in our tradition allows disarmament simply because [the defendant] belongs to a category of people, drug users, that Congress has categorically deemed dangerous,” their ruling said.

In Baxter, the Eighth Circuit ruled 922(g)(3) unconstitutional as applied to the facts in the case.

Judges in that case wrote that there were insufficient factual findings in the record “for this Court to review Baxter’s as-applied Second Amendment challenge.” Nevertheless, the they wrote, “We reverse the district court’s ruling on Baxter’s as-applied Second Amendment challenge and remand to the district court for further proceedings consistent with this opinion.”

In recent weeks, the government has sought further time from the court to decide whether to seek an appeal in the other cases. And when DOJ filed its appeal in Cooper, it further asked the court to slow walk the case, requesting justices “hold the petition for a writ of certiorari pending the disposition of the petition in United States v. Hemani…and should then dispose of this petition as appropriate.”

One reason DOJ could be focused on the high court taking up Hemani in particular is that the defendant is not only a cannabis user but also a user of cocaine who’s sold drugs in the past, perhaps reasoning that he is a less sympathetic face of drug consumers’ gun rights. Defendants in the other cases were merely found in possession of both a firearm and marijuana.

If the Supreme Court takes up Hemani and declares 922(g)(3) constitutional, such a ruling could could mean government wins in the remaining cases.

One risk to the government appealing the lower court rulings are that if the Supreme Court does take the case, justices may in fact rule unfavorably to the government, possibly cementing that § 922(g)(3) is—in at least some cases—unconstitutional.

A number of federal courts in recent months have cast doubt on the legality of § 922(g)(3), finding generally that while the ban on gun ownership among drug users may not be entirely unconstitutional, there’s scant historical precedent for such a broad restriction of Second Amendment rights on an entire a category of people.

Earlier this year, for example, a federal judge in Rhode Island ruled that the ban was unconstitutional as applied to two defendants, writing that the government failed to establish that the “sweeping” prohibition against gun ownership by marijuana users was grounded in historical precedent.

In another case earlier this year, a Fifth Circuit panel ruled that the firearms ban was unconstitutional as applied to least one defendant. That ruling came on the heels of a string of other judicial decisions casting doubt on the legality of the ban.

A federal judge in El Paso, for instance, ruled late last year that the government’s ongoing ban on gun ownership by habitual marijuana users is unconstitutional in the case of a defendant who earlier pleaded guilty to the criminal charge. The court allowed the man to withdraw the plea and ordered that the indictment against him be dismissed.

Another panel of judges, on the U.S. Court of Appeals for the Tenth Circuit, heard oral arguments in November in the government’s appeal of a district court ruling that deemed the gun ban unconstitutional.

Much of the panel’s discussion at oral argument in that case surrounded whether the underlying dispute was a facial challenge to the gun ban or an as-applied challenge. And, as in other cases, judges zeroed in on whether or not that defendant was actually under the influence of marijuana while in possession of a firearm.

In a number of the ongoing cases, DOJ has argued that the prohibition on gun ownership by marijuana users is also supported by a recent U.S. Supreme Court decision, U.S. v. Rahimi, that upheld the government’s ability to limit the Second Amendment rights of people with domestic violence restraining orders.

DOJ has made such arguments, for example, in favor of the firearms ban in a case in a case in the U.S. Court of Appeals for the Eleventh Circuit. In that matter, a group of Florida medical cannabis patients contends that their Second Amendment rights are being violated because they cannot lawfully buy firearms so long as they are using cannabis as medicine, despite acting in compliance with state law.

DOJ under President Joe Biden consistently argued that medical marijuana patients who possess firearms “endanger public safety,” “pose a greater risk of suicide” and are more likely to commit crimes “to fund their drug habit.”

It remains unclear how the Trump administration will approach the cases. At a NRA conference in 2023, Trump suggested there might be a link between the use of “genetically engineered” marijuana and mass shootings. He listed a number of controversial and unproven factors that he said at the time he would direct the Food and Drug Administration (FDA) to investigate as possibly causing the ongoing scourge of mass shooting afflicting the country.

“We have to look at whether common psychiatric drugs, as well as genetically engineered cannabis and other narcotics, are causing psychotic breaks” that lead to gun violence, he said.

DOJ has claimed in multiple federal cases over the past several years that the statute banning cannabis consumers from owning or possessing guns is constitutional because it’s consistent with the nation’s history of disarming “dangerous” individuals.

In 2023, for example, the Justice Department told the U.S. Court of Appeals for the Third Circuit that historical precedent “comfortably” supports the restriction. Cannabis consumers with guns pose a unique danger to society, the Biden administration claimed, in part because they’re “unlikely” to store their weapon properly.

Last year, Biden’s son Hunter was convicted by a federal jury of violating statute by buying and possessing a gun while an active user of crack cocaine. Two Republican congressmen challenged the basis of that conviction, with one pointing out that there are “millions of marijuana users” who own guns but should not be prosecuted.

The situation has caused confusion among medical marijuana patients, state lawmakers and advocacy groups, among others. The National Rifle Association’s (NRA) lobbying arm said recently that the court rulings on the cannabis and guns issue have “led to a confusing regulatory landscape” that have impacted Americans’ Second Amendment rights.

“Marijuana use is no longer limited to the domain of indigenous religious customs or youth-oriented counterculture and now includes a wide variety of people who use it for medicinal or recreational reasons,” said the advocacy group, which does not have an official stance on cannabis policy generally. “Many of these individuals are otherwise law-abiding and productive members of their communities and want to exercise their right to keep and bear arms.”

Meanwhile, some states have passed their own laws either further restricting or attempting to preserve gun rights as they relate to marijuana. Recently, for example, a Pennsylvania lawmaker introduced a bill meant to remove state barriers to medical marijuana patients carrying firearms.

Colorado activists also attempted to qualify an initiative for November’s ballot that would have protected the Second Amendment rights of marijuana consumers in that state, but the campaign’s signature-gathering drive ultimately fell short.

As 2024 drew to a close, the ATF issued a warning to Kentucky residents that, if they choose to participate in the state’s medical marijuana program that’s set to launch imminently, they will be prohibited from buying or possessing firearms under federal law.

The official said that while people who already own firearms aren’t “expected to” turn them over if they become state-legal cannabis patients, those who “wish to follow federal law and not be in violation of it” must “make the decision to divest themselves of those firearms.”

Since then, bipartisan state lawmakers have introduced legislation that would urge Kentucky’s representatives in Congress to amend federal law to clarify that users of medical marijuana may legally possess firearms, though no action has since been taken on that bill.

Kentucky Gov. Andy Beshear (D) said in January that he supported the legislature’s effort to urge the state’s congressional delegation to call for federal reforms to protect the Second Amendment rights of medical marijuana patients, but the governor added that he’d like to see even more sweeping change on the federal level.

“I think the right way to deal with that is not just to focus on that issue, but to change the schedule of marijuana,” Beshear said at a press conference. “What we need to change is the overall marijuana policy by the federal government.”

Read the judge’s full ruling in Greene v. Bondi below:

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Become a patron at Patreon!





Source link

mscannabiz.com
Author: mscannabiz.com

MScannaBIZ for all you Mississippi Cannabis News and Information.

Continue Reading

featured

5 Ways Dispensaries Can Build Momentum Around 7/10

Published

on


Every cannabis retailer knows the power of 4/20. But what about 7/10?

Just like 4/20, which took years—if not decades—to become the mainstream cannabis moment it is today, 7/10 is still in its early growth phase. Known as Oil Day, July 10 has emerged as a rising occasion for cannabis concentrates. Yet despite years of industry effort, 7/10 has yet to achieve the mainstream traction of its April counterpart. But that’s not a failure; it’s an opportunity. 

Advertisment: Cannabis Business Times » Cannabis Business Times Best Cannabis Companies to Work For » CBT Best Companies 2026 ROS Parallax Reveal » bcc-ads-730x570
Advertisment: Cannabis Business Times » Cannabis Business Times Best Cannabis Companies to Work For » CBT Best Companies 2026 ROS Parallax Reveal » bcc-ads-730x570

Holiday or Hype? Sweed’s 7/10 Retail Data Challenges Assumptions

7/10 is a blank slate with strong potential, but most consumers aren’t yet connecting with it.

In July 2024, oil-based products like vapes and concentrates made up 30% of all dispensary revenue, with vape carts neck-and-neck with flower in nearly every sales metric, according to Sweed, an innovative retail management platform for the cannabis industry.

Advertisment: Hanwha Vision » Hanwha Vision Order 78 » CBT ROS 300x250 Medium Rectangle July 2025 » D53_Cannabis-Business-Times_300x250_v1

Interestingly, the purchase of oil products actually peaked after 7/10, with August outperforming July across most categories. Sweed’s data suggests that 7/10 does not drive immediate retail spikes the way 4/20 does, and that consumer enthusiasm for oil-based products builds after the holiday.

Advertisment: Frank Mayer » Frank Mayer Order 84 » CBT ROS Medium Rectangle 300x250 July 2025 » CBT Web Ad - July 2025

Instead of expecting immediate returns, Sweed recommends that retailers take a leadership role in shaping what 7/10 means, and that begins with education, accessibility, and consistent storytelling. Here are five tips to help retailers make the most of 7/10 and build a foundation for long-term success:

1. Explain the Holiday Before You Try to Sell It

Most shoppers don’t know what “710” refers to, let alone how to celebrate it. Dispensaries can lead by demystifying the holiday with simple in-store or online education. A counter card at the register, a post on Instagram, or a short video on a display screen can go a long way in explaining why the holiday is called 7/10, what oil-based products are, and how they differ from flower or edibles. Simple in-store and digital explainers can turn a passive shopper into an engaged one.

2. Launch a “Cannabis Oils 101” Campaign

Data from Sweed suggests that many consumers are curious about concentrates but hesitant to dive in. Creating low-pressure education events or budtender Q&A sessions the week before and after 7/10 can help demystify oil-based products. Educational signage or short videos showing how to use vape carts, dab rigs, or applicators can boost confidence and interest. Also, using friendly, accessible terms like “starter-friendly” or “beginner concentrate” can make trying these products feel less intimidating to first-timers.

3. Position Oil Products as a Lifestyle Fit

The diversity of oil-based formats, from disposable vape pens to potent live resin dabs, makes them ideal for a range of needs, but most shoppers don’t know this. Retailers can help by connecting oil products to everyday intentions. For instance, a vape pen might be “perfect for a hike,” and a discreet cartridge could be marketed as “great for daytime use.” Another way to reduce decision fatigue is to create curated product bundles, like “The Curious Dabber Starter Pack” or “Vape & Go Essentials,” that introduce customers to different formats based on their lifestyle or goals.

4. Turn Budtenders into Oil Ambassadors

Budtenders are among the most trusted voices in the cannabis retail experience. To make the most of 7/10 and beyond, dispensaries should equip their staff with clear, easy-to-understand talking points about oil-based products, including information about effects, use cases, and safe dosing.

Also, offering incentives to budtenders for upselling or recommending concentrate formats throughout July can boost engagement, especially if the focus remains on education rather than pure conversion.

Lastly, featuring “staff picks” for oils, along with short notes about why a product is loved by the team, builds trust and personal connection with shoppers.

5. Extend the Holiday: Make July to August Your Oil Season

Since Sweed’s data found that oil product performance is often stronger in August than in July, Sweed recommends treating the 7/10 holiday not as a single day, but as a launchpad for a longer seasonal campaign.

Retailers can start building awareness in early July and continue promotions and educational efforts into late summer. A themed campaign like “Summer of Oil” can provide a flexible framework for rolling out educational campaigns, spotlighting new or limited-edition products, and running evolving deals throughout the summer. By making oil education and discovery a season-long experience, dispensaries can capture greater sales while deepening customer relationships.



Source link

mscannabiz.com
Author: mscannabiz.com

MScannaBIZ for all you Mississippi Cannabis News and Information.

Continue Reading

featured

Cannabis banking will move “hopefully sooner than later,” senator says (Newsletter: July 7, 2025)

Published

on


Czech Republic marijuana & psilocybin bill passes; VA secretary: Psychedelics are “phenomenal” in treating veterans; Study on cannabis and sex

Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day.

Your support makes Marijuana Moment possible…

Free to read (but not free to produce)! We’re proud of our newsletter and the reporting we publish at Marijuana Moment, and we’re happy to provide it for free. But it takes a lot of work and resources to make this happen.

If you value Marijuana Moment, invest in our success on Patreon so we can expand our coverage and more readers can benefit: https://www.patreon.com/marijuanamoment

/ TOP THINGS TO KNOW

Sen. Jeff Merkley (D-OR) told Marijuana Moment that a cannabis banking bill will be taken up “hopefully sooner than later” but that “other things like war and reconciliation” have prevented key lawmakers from prioritizing the legislation.

  • “We’ve tried to schedule several meetings. We keep trying to do it.”

Veterans Affairs Secretary Doug Collins said he’s “particularly proud” of efforts to expand research on the benefits of psychedelics, which he said “have been phenomenal” in helping people with PTSD and traumatic brain injuries.

The Czech Republic Senate passed a bill to legalize possession and home cultivation of marijuana and allow medical use of psilocybin, sending it to the desk of President Petr Pavel to be signed into law.

A new study shows that “more frequent cannabis use was linked with greater daily sexual desire.”

  • “Participants reported significantly higher sexual desire and lower sexual distress on days they used cannabis compared to non-use days.”

California’s Senate president pro tem defended his resistance to proposals to prevent a marijuana tax increase, saying, “any freeze will create a budget shortfall which would impact critical community programs funded by cannabis tax dollars.”

Texas medical cannabis companies are pushing lawmakers to ban synthetic delta-8 THC and restrict consumable hemp products to adults over the age of 21 in an upcoming special session this month.

The Rhode Island Cannabis Control Commission is proceeding with the application process for a medical marijuana dispensary license with previously qualified applicants from an earlier selection round.

All seven of Delaware’s medical cannabis operators have converted to adult-use marijuana sales and will be able to begin selling recreational products on August 1.

A new survey shows that marijuana consumers in the Des Moines, Iowa area are generally employed, own a home, vote regularly, pay their taxes and are involved in their communities—smashing “lazy stoner” stereotypes.

/ FEDERAL

The Bureau of Land Management announced its intent to award a contract concerning “reclamation activities from public land cannabis cultivation complexes.”

Former Centers for Disease Control and Prevention Director Robert Redfield authored an op-ed detailing concerns about a “potent synthetic opioid masquerading as natural kratom.”

Sen. Marsha Blackburn (R-TN) filed an amendment to require online platforms to take steps to prevent minors’ access to potentially sensitive content—including advertisements for cannabis products and certain other drugs and services.

/ STATES

The vice chair of the Maryland Senate Judicial Proceedings Committee said lawmakers will “unquestionably come back and remedy” any errors in an expungements law that may have omitted certain marijuana convictions pardoned by Gov. Wes Moore (D).

The Georgia House Blue-Ribbon Study Committee on Georgia’s Medical Marijuana and Hemp Policies announced its meeting dates and locations.

An Arizona judge denied a preliminary injunction against the attorney general’s move to crack down on intoxicating hemp products.

California regulators announced recalls of marijuana products due to various issues.

Minnesota regulators issued a consumer advisory about cannabis gummies due to product mislabeling and THC content above the legal limit.

Colorado regulators published a bulletin reminding marijuana business licenses of the upcoming second annual payment for the two-year license term.

Michigan officials are distributing free locking bags for marijuana in order to help prevent accidental ingestion by children.

Missouri regulators are accepting applications to participate in the Missouri Cannabis Regulation Collaborative.


Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.


Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.

/ LOCAL

Dallas, Texas officials are asking a judge to issue a temporary injunction against the city’s voter-approved marijuana decriminalization law.

/ INTERNATIONAL

An Israeli Ministry of Justice official issued an opinion upholding the minister of finance’s rejection of tariffs on Canadian medical cannabis imports.

/ SCIENCE & HEALTH

A study “illustrates the potential of phytocannabinoids as antifungal treatments and opens up new routes towards development of novel antifungal drugs.”

A review concluded that “evidence from case studies, preclinical research, and early phase clinical trials suggests that psychedelics may alleviate pain in conditions such as cluster headaches, migraines, fibromyalgia, and chronic pain syndromes.”

/ BUSINESS

Blum Holdings, Inc. is acquiring another dispensary in Northern California.

Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox.

Photo courtesy of Chris Wallis // Side Pocket Images.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Become a patron at Patreon!





Source link

mscannabiz.com
Author: mscannabiz.com

MScannaBIZ for all you Mississippi Cannabis News and Information.

Continue Reading
featured31 minutes ago

Federal Judge Rejects Pennsylvania Prosecutor’s Lawsuit Challenging Ban On Marijuana Consumer Gun Ownership

featured2 hours ago

5 Ways Dispensaries Can Build Momentum Around 7/10

featured3 hours ago

Cannabis banking will move “hopefully sooner than later,” senator says (Newsletter: July 7, 2025)

Mississippi Cannabis News19 hours ago

Mississippi Band of Choctaw Indians Approve Referendum Allowing Tribe to Explore Cannabis Legalization

featured20 hours ago

Slipknot’s Sid Wilson Proposes to Kelly Osbourne During Ozzy’s Farewell Show

featured22 hours ago

Marijuana Users In Iowa Are Engaged And Active Citizens, Survey Shows—Smashing ‘Lazy Stoner’ Stereotypes

featured23 hours ago

Here’s Where To Buy Legal Recreational Marijuana In Delaware Next Month

video1 day ago

Fireworks, marijuana and cash found in Bronx apartment – NBC New York

video1 day ago

How often are marijuana cases federally prosecuted?

featured2 days ago

A Brief History of Getting High

featured2 days ago

Rhode Island Marijuana Regulators Seeking Applications For New Dispensary In State’s Northern Region

featured2 days ago

Texas Medical Marijuana Industry Wants Lawmakers To Ban Synthetic Delta-8 THC And Restrict Hemp Products To Adults

featured2 days ago

California Cannabis Operators Warn That New Tax Hike ‘Could Kill This Industry’

featured2 days ago

High Times Greats: Jim Morrison

video2 days ago

New cannabis tax increase is a high concern for California dispensaries, customers

featured3 days ago

A Brief History of High Times (2019)

video3 days ago

Georgia veterans suffering from PTSD push for medical cannabis expansion on Fourth of July

featured3 days ago

A Brief Global History of the War on Cannabis

featured3 days ago

The Evolution of Cannabis in Film

featured3 days ago

High Times Is Home Again

featured3 days ago

Dope As Yola Becomes First Weedtuber to Hit 2 Million Subscribers

video3 days ago

$20M worth of cocaine, marijuana seized in Caribbean Sea: USCG

featured3 days ago

Will Success Spoil Cheech & Chong? Of Course (1980)

featured3 days ago

Prescription-Only Rule Takes Hold Amid Political Ouster

Trending